Beacon Investment Advisors’s Haemonetics HAE Stock Holding History

Beacon Investment Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.09M	Buy	37,115 +5,253	+16%	+$342K	0.79%	32
2025 Q4	$2.55M	Buy	31,862 +138	+0.4%	+$9.27K	1.02%	28
2025 Q3	$1.55M	Buy	31,724 +954	+3%	+$59.1K	0.63%	50
2025 Q2	$2.27M	Buy	30,770 +50	+0.2%	+$3.31K	0.98%	27
2025 Q1	$1.95M	Buy	30,720 +18,086	+143%	+$1.23M	0.92%	29
2024 Q4	$987K	Buy	12,634 +87	+0.7%	+$6.99K	0.46%	65
2024 Q3	$1.01M	Buy	12,547 +385	+3%	+$31.1K	0.48%	63
2024 Q2	$1.01M	Buy	12,162 +30	+0.2%	+$2.64K	0.51%	60
2024 Q1	$1.04M	Buy	12,132 +75	+0.6%	+$5.89K	0.59%	54
2023 Q4	$1.03M	Hold	12,057	–	–	0.66%	45
2023 Q3	$1.08M	Sell	12,057 -15	-0.1%	-$1.34K	0.76%	44
2023 Q2	$1.03M	Sell	12,072 -295	-2%	-$24.9K	0.7%	45
2023 Q1	$1.02M	Buy	12,367 +132	+1%	+$10.7K	0.75%	43
2022 Q4	$962K	Buy	+12,235	New	+$983K	0.8%	42

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Beacon Investment Advisors's HAE Position: Q1 2026 in Review

Beacon Investment Advisors increased its Haemonetics (HAE) stake by 16% in Q1 2026, buying an estimated $342K and bringing the position to 37,115 shares worth $2.09M. The position accounts for 0.79% of the portfolio, ranked #32.

Beacon Investment Advisors first reported a position in HAE in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.55M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Beacon Investment Advisors held 37,115 shares of Haemonetics worth $2.09M as of Q1 2026.
Beacon Investment Advisors bought 5,253 Haemonetics shares in Q1 2026, an estimated $342K.
Haemonetics made up 0.79% of Beacon Investment Advisors's portfolio in Q1 2026, its #32 holding.
Beacon Investment Advisors first reported a position in Haemonetics in Q4 2022 and has held it in 14 quarters since.
Beacon Investment Advisors's Haemonetics position peaked at $2.55M in Q4 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Beacon Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.